A#1747 RA mortality by race/ethnicity Database study >200,000 pts had RA as contributing cause of death 5.1 ASMR in American Indian >>> all other groups No decr over time in grp, unlike other grps Odds of death 1.67 compared to white pop 10.8x higher in pts <44 #ACR24 @RheumNow https://t.co/nXLcQkQPu4

• https://x.com/ericdeinmd/status/1858254655928852760/photo/1
• https://x.com/ericdeinmd/status/1858254655928852760/photo/1

On now: The Great Debate - is MCTD a distinct clinical entity? @DrLisaCS reviews the history of MCTD classification criteria and its evolution Kasukawa criteria may be most sensitive in one cohort @RheumNow #ACR24 https://t.co/rDHafZVL1I

• https://x.com/Dr_Brian_MD/status/1858249504501194915/photo/1

A study showed the sex differences in serum proteomic profiles of males and females with PsA. Key findings: -Identified 741 unique proteins in male PsA patients vs. controls vs. 31 in females. - Several sex-specific pathways, including immune cell functions and cytokine… https://t.co/erC599Zbuj

• https://x.com/i/web/status/1858250004697391431

Chinoy et al. Baricitinib in IIM. Delayed-start clinical trial. 15 patients. 14/15 improved at 24 weeks (the other withdrew). 50% vs 100% at week 12 (delayed start group initiation). Stats confuse me a bit here but promising. @RheumNow #ACR24 Abstr#1731 https://t.co/orewsxbPpL https://t.co/5AyRpYJdec

• Baricitinib in the Treatment of Adult Idiopathic Inflammatory Myopathy: A Rando…
• https://x.com/RichardPAConway/status/1858251010788991334/photo/1

A#1746 companion for RA Like plenary for PsA, PBO response incr w time 1%/yr More trials in less affluent countries may be related to increasing PBO response in trials Possible reason: access to health care improves PBO in less affluent areas @RheumNow #ACR24 https://t.co/S3LffF8vPH

• https://twitter.com/ericdeinmd/status/1857803974922903912

RA patients on TOF with h/o ASCVD have 4x higher risk of MACE without statin (vs. TNFi). Prioritize statins for heart health in RA! #ACR24 @RheumNow ABST#1745 https://t.co/jRqXNU2T6d

• https://x.com/JihaRheum/status/1858252521044893744/photo/1
• https://x.com/JihaRheum/status/1858252521044893744/photo/1

The odds of axSpA patients developing fractures was lower among those on TNFi vs DMaRDs or NSAIDs accdg to this study by NGeorge et al. axSpA pts are at high risk of fractures & drugs that mitigate these risks are important. More robust data are needed @RheumNow #ACR24 abs1439 https://t.co/ZSV3og5N5x

• https://x.com/RHEUMarampa/status/1858252752427626764/photo/1

A#1745 Post-hoc ORAL Surveillance - statin <1/4 on a statin, only 53% h/o ASCVD on statin Incr in LDL was less on Tofa pts on statin Among those on b/l statins, there is no incr risk compare to TNFi, esp pts h/o ASCVD If high risk on tofa, statin helps! @RheumNow #ACR24 #ACRBest https://t.co/7MGgUk7tfI

• https://x.com/ericdeinmd/status/1858249048085434638/photo/1
• https://x.com/ericdeinmd/status/1858249048085434638/photo/1
• https://x.com/ericdeinmd/status/1858249048085434638/photo/1

Wallace et al. Case control study. 648 cases 1241 controls. Cumulative glucocorticoid dose and risk MACE. Dose dependent increase in risk, OR 1.01 for 10% increase GC, 1.21 for 10-fold increase GC. @RheumNow #ACR24 Abstr#1719 https://t.co/wraiWOl1dv https://t.co/feht58RDNc

• Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a…
• https://x.com/RichardPAConway/status/1858248746078785887/photo/1

Single cell TCR sequence study explores the limitations of TRBV9-depleting therapies in axial spondyloarthritis. Key findings: - Identified a clonally expanded TRBV5-5+ TCR in HLA-B27+ acute anterior uveitis. - Alternative TRBVs may retain pathogenicity and evade anti-TRBV9… https://t.co/Aj8oslsTNX

• https://x.com/i/web/status/1858246230763253795

📝Bimekizumab 160mg Q4 weeks in r-axSpA and nr-axSpA achieved substantial reductions in MRI inflammation at Wk 16 maintaining to Wk 52. -PBO‑switchers (started at week 16) reached similar levels of improvement as continuous BKZ pts at Wk 52. Abst#1757 #ACR24 @RheumNow https://t.co/m9sdAbFqI9

• https://x.com/AdelaCastro222/status/1858246229513400637/photo/1
• https://x.com/AdelaCastro222/status/1858246229513400637/photo/1

A#1744 AI for RA to improve scheduling in UK 39% pts meet quality metric for early intervention Input: RF, CRP, CCP, gender, age -> 51% accuracy (compare to first appt clinical accur 46%) Focusing on highest risk -> 88% accuracy -> 50% wait time for high-risk pts #ACR24 @RheumNow

Strive for remission (CDAI ≤2.8) to achieve better functional outcomes in RA #ACR24 @RheumNow ABST#1743 https://t.co/qpsTF54rmW

• https://x.com/JihaRheum/status/1858243713019044198/photo/1